A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Advanced Solid Tumors

Interventions

DRUG

TAS-102

Trial Locations (8)

Pittsburgh Clinical Site, Pittsburgh

Baltimore Clinical Site, Baltimore

Cleveland Clinical Site, Cleveland

Dallas Clinical Site, Dallas

Mayo Clinic, Scottsdale

Santa Monica Clinical Site, Santa Monica

Duarte Clinical Site, Duarte

Boston Clinical Site, Boston

All Listed Sponsors

lead

Taiho Oncology, Inc.

INDUSTRY

NCT02301104 - A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | Biotech Hunter | Biotech Hunter